Atherosclerosis
Volume 196, Issue 2 , Pages 505-513 , February 2008

CETP activity variation in mice does not affect two major HDL antiatherogenic properties: Macrophage-specific reverse cholesterol transport and LDL antioxidant protection

  • Noemí Rotllan

      Affiliations

    • Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    • ,
  • Laura Calpe-Berdiel

      Affiliations

    • Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    • ,
  • Amy Guillaumet-Adkins

      Affiliations

    • Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Barcelona, Spain
    • ,
  • Songül Süren-Castillo

      Affiliations

    • Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    • ,
  • Francisco Blanco-Vaca

      Affiliations

    • Department of Biochemistry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    • Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Barcelona, Spain
    • Corresponding Author InformationCorresponding authors at: Servei de Bioquímica, Hospital de la Santa Creu i Sant Pau, Antoni M Claret 167, 08025 Barcelona, Spain. Tel.: +34 93 2919451; fax: +34 93 2919196.
    • ,
  • Joan Carles Escolà-Gil

      Affiliations

    • Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    • Corresponding Author InformationCorresponding authors at: Servei de Bioquímica, Hospital de la Santa Creu i Sant Pau, Antoni M Claret 167, 08025 Barcelona, Spain. Tel.: +34 93 2919451; fax: +34 93 2919196.

Received 16 February 2007 ,Revised 9 May 2007 ,Accepted 10 May 2007.

References 

  1. Gordon DJ, Rifkind BM. High-density lipoprotein—the clinical implications of recent studies. N Engl J Med. 1989;321:1311–1316
  2. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res. 1993;34:1255–1274
  3. de Grooth GJ, Klerkx AH, Stroes ES, et al. A review of CETP and its relation to atherosclerosis. J Lipid Res. 2004;45:1967–1974
  4. Forrester JS, Makkar R, Shah PK. Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition: an update for clinicians. Circulation. 2005;111:1847–1854
  5. Klerkx AH, El Harchaoui K, van der Steeg WA, et al. Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels. pathways by which modulation of cetp activity may alter atherogenesis. Arterioscler Thromb Vasc Biol. 2006;26:706–715
  6. Agellon LB, Walsh A, Hayek T, et al. Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. J Biol Chem. 1991;266:10796–10801
  7. Marotti KR, Castle CK, Murray RW, et al. The role of cholesteryl ester transfer protein in primate apolipoprotein A-I metabolism. Insights from studies with transgenic mice. Arterioscler Thromb. 1992;12:736–744
  8. Escola-Gil JC, Calpe-Berdiel L, Palomer X, et al. Antiatherogenic role of high-density lipoproteins: insights from genetically engineered-mice. Front Biosci. 2006;11:1328–1348
  9. Marotti KR, Castle CK, Boyle TP, et al. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature. 1993;364:73–75
  10. Hayek T, Masucci-Magoulas L, Jiang X, et al. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J Clin Invest. 1995;96:2071–2074
  11. Plump AS, Masucci-Magoulas L, Bruce C, et al. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler Thromb Vasc Biol. 1999;19:1105–1110
  12. Escola-Gil JC, Julve J, Marzal-Casacuberta A, et al. ApoA-II expression in CETP transgenic mice increases VLDL production and impairs VLDL clearance. J Lipid Res. 2001;42:241–248
  13. Westerterp M, van der Hoogt CC, de Haan W, et al. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice. Arterioscler Thromb Vasc Biol. 2006;26:2552–2559
  14. Foger B, Chase M, Amar MJ, et al. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. J Biol Chem. 1999;274:36912–36920
  15. MacLean PS, Bower JF, Vadlamudi S, et al. Cholesteryl ester transfer protein expression prevents diet-induced atherosclerotic lesions in male db/db mice. Arterioscler Thromb Vasc Biol. 2003;23:1412–1415
  16. Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov. 2005;4:193–205
  17. Osono Y, Woollett LA, Marotti KR, et al. Centripetal cholesterol flux from extrahepatic organs to the liver is independent of the concentration of high density lipoprotein-cholesterol in plasma. Proc Natl Acad Sci USA. 1996;93:4114–4119
  18. Alam K, Meidell RS, Spady DK. Effect of up-regulating individual steps in the reverse cholesterol transport pathway on reverse cholesterol transport in normolipidemic mice. J Biol Chem. 2001;276:15641–15649
  19. Harada LM, Amigo L, Cazita PM, et al. CETP expression enhances liver HDL-cholesteryl ester uptake but does not alter VLDL and biliary lipid secretion. Atherosclerosis. 2007;191:313–318
  20. Brousseau ME, Diffenderfer MR, Millar JS, et al. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol. 2005;25:1057–1064
  21. Zhang Y, Zanotti I, Reilly MP, et al. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation. 2003;108:661–663
  22. Rotllan N, Ribas V, Calpe-Berdiel L, et al. Overexpression of human apolipoprotein A-II in transgenic mice does not impair macrophage-specific reverse cholesterol transport in vivo. Arterioscler Thromb Vasc Biol. 2005;25:e128–e132
  23. Calpe-Berdiel L, Rotllan N, Palomer X, et al. Direct evidence in vivo of impaired macrophage-specific reverse cholesterol transport in ATP-binding cassette transporter A1-deficient mice. Biochim Biophys Acta. 2005;1738:6–9
  24. Moore RE, Navab M, Millar JS, et al. Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation. Circ Res. 2005;97:763–771
  25. Noto H, Kawamura M, Hashimoto Y, et al. Modulation of HDL metabolism by probucol in complete cholesteryl ester transfer protein deficiency. Atherosclerosis. 2003;171:131–136
  26. Bisoendial RJ, Hovingh GK, El Harchaoui K, et al. Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia. Arterioscler Thromb Vasc Biol. 2005;25:e133–e134
  27. Zhang B, Fan P, Shimoji E, et al. Inhibition of cholesteryl ester transfer protein activity by JTT-705 increases apolipoprotein E-containing high-density lipoprotein and favorably affects the function and enzyme composition of high-density lipoprotein in rabbits. Arterioscler Thromb Vasc Biol. 2004;24:1910–1915
  28. Huang Z, Inazu A, Nohara A, et al. Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clin Sci (Lond). 2002;103:587–594
  29. Trocho C, Escola-Gil JC, Ribas V, et al. Phenytoin treatment reduces atherosclerosis in mice through mechanisms independent of plasma HDL-cholesterol concentration. Atherosclerosis. 2004;174:275–285
  30. Ribas V, Sanchez-Quesada JL, Anton R, et al. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential. Circ Res. 2004;95:789–797
  31. Calpe-Berdiel L, Escola-Gil JC, Ribas V, et al. Changes in intestinal and liver global gene expression in response to a phytosterol-enriched diet. Atherosclerosis. 2005;181:75–85
  32. Marzal-Casacuberta A, Blanco-Vaca F, Ishida BY, et al. Functional lecithin:cholesterol acyltransferase deficiency and high density lipoprotein deficiency in transgenic mice overexpressing human apolipoprotein A-II. J Biol Chem. 1996;271:6720–6728
  33. Serrat-Serrat J, Ordonez-Llanos J, Serra-Grima R, et al. Marathon runners presented lower serum cholesteryl ester transfer activity than sedentary subjects. Atherosclerosis. 1993;101:43–49
  34. Stein O, Dabach Y, Hollander G, et al. Reverse cholesterol transport in mice expressing simian cholesteryl ester transfer protein. Atherosclerosis. 2002;164:73–78
  35. Cuchel M, Rader DJ. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis?. Circulation. 2006;113:2548–2555
  36. Rader DJ. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest. 2006;116:3090–3100
  37. Masson D, Staels B, Gautier T, et al. Cholesteryl ester transfer protein modulates the effect of liver X receptor agonists on cholesterol transport and excretion in the mouse. J Lipid Res. 2004;45:543–550
  38. Van Eck M, Ye D, Hildebrand RB, et al. Important role for bone marrow-derived cholesteryl ester transfer protein in lipoprotein cholesterol redistribution and atherosclerotic lesion development in LDL receptor knockout mice. Circ Res. 2007;100:678–685
  39. Zhang Y, Da Silva JR, Reilly M, et al. Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. J Clin Invest. 2005;115:2870–2874
  40. Gauthier A, Lau P, Zha X, et al. Cholesteryl ester transfer protein directly mediates selective uptake of high density lipoprotein cholesteryl esters by the liver. Arterioscler Thromb Vasc Biol. 2005;25:2177–2184
  41. Cazita PM, Berti JA, Aoki C, et al. Cholesteryl ester transfer protein expression attenuates atherosclerosis in ovariectomized mice. J Lipid Res. 2003;44:33–40
  42. Chiang JY. Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms. J Hepatol. 2004;40:539–551
  43. Luo Y, Tall AR. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. J Clin Invest. 2000;105:513–520
  44. Blanco-Vaca F, Escola-Gil JC, Martin-Campos JM, et al. Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein. J Lipid Res. 2001;42:1727–1739
  45. Chiba H, Akita H, Kotani K, et al. Complete cholesteryl ester transfer protein deficiency increases oxidized-LDL in plasma. Rinsho Byori. 1997;45:55–57

PII: S0021-9150(07)00339-5

doi: 10.1016/j.atherosclerosis.2007.05.007

Atherosclerosis
Volume 196, Issue 2 , Pages 505-513 , February 2008

Article Tools

* Image Usage & Resolution